Alumis INC Form 4 insider transactions

Foresite Capital Management VI LLC and related entities reported the purchase of 72,212 shares of ALUMIS INC. common stock at $7.38 per share, increasing their beneficial ownership.

James B. Tananbaum, a Director and 10% owner of ALUMIS INC., acquired 72,212 shares of common stock for $7.38 per share, totaling approximately $533,000.

Foresite Labs, a 10% owner and director, reported an acquisition of 72,212 shares of ALUMIS INC. common stock at $7.38 per share.

Alumis Inc. Director Srinivas Akkaraju reported the purchase of 125,743 shares of common stock for approximately $905,349 on November 20, 2025.

Foresite Labs, a 10% owner and director of ALUMIS INC., significantly increased its indirect beneficial ownership through multiple common stock purchases in mid-November 2025.

Foresite Capital entities, including a 10% owner and director, reported significant purchases of ALUMIS INC. common stock totaling over 500,000 shares across multiple transactions in November 2025.

James B. Tananbaum, a Director and 10% owner of ALUMIS INC., reported the acquisition of 507,874 shares of common stock across multiple transactions in mid-November 2025.

Alumis Inc. Director Srinivas Akkaraju, through affiliated funds, acquired over 241,000 shares of common stock across three transactions in mid-November 2025.

ALUMIS Director Srinivas Akkaraju reports an indirect purchase of 276,179 common shares through Samsara Opportunity Fund.

Alumis Inc. Director Lynn A. Tetrault was granted 49,800 stock options with an exercise price of $4.10 per share, vesting over time and upon certain events.

Alumis Inc. director Zhengbin Yao was granted 49,800 stock options with an exercise price of $4.10, vesting over time and upon specific corporate events.

Alumis Inc. Director Sapna Srivastava was granted 49,800 stock options with an exercise price of $4.10, vesting over time or upon a change in control.

Alumis Inc. Director Patrick Machado was granted 49,800 stock options with an exercise price of $4.10, vesting over the next year or upon specific corporate events.

Alumis Inc. Director Srinivas Akkaraju was granted 49,800 stock options with an exercise price of $4.10, vesting over one year or upon the 2026 annual stockholder meeting.

Alumis Inc.'s Chief Legal Officer, Sanam Pangali, was granted 10,000 restricted stock units and options to purchase 40,000 shares of common stock, aligning executive incentives with long-term company performance.

Derrick Richardson, SVP of People and Culture at Alumis Inc., was granted 42,800 restricted stock units and options to purchase 64,200 shares of common stock.

Alumis Inc.'s Chief Financial Officer, John R. Schroer, was granted 28,000 restricted stock units and options to purchase 111,950 shares of common stock, effective July 29, 2025.

Alumis Inc.'s Chief Business & Strategy Officer, Roy C. Hardiman, was granted 28,000 restricted stock units and 111,950 stock options, alongside an acquisition of 3,000 shares via the employee stock purchase plan.

Alumis Inc.'s Chief Scientific Officer, David M. Goldstein, reported the acquisition of 27,000 restricted stock units and 107,950 stock options as part of compensation, alongside existing beneficial ownership.

Alumis Inc.'s Chief Medical Officer, Jorn Drappa, was granted 25,450 restricted stock units and 101,850 stock options, aligning executive compensation with long-term company performance.

Alumis Inc.'s Chief Development Officer, Mark Christopher Bradley, was granted 26,750 restricted stock units and options to purchase 107,100 shares of common stock, signaling continued executive alignment with company performance.

Alumis Inc.'s President, CEO, and Chairman, Martin Babler, reported the acquisition of 3,000 common shares and a grant of 812,000 stock options with a strike price of $3.95.

ALUMIS Inc.'s Chief Legal Officer, Sanam Pangali, acquired 100,000 stock options with an exercise price of $3.56, set to vest over four years.

Alumis Inc. Director Srinivas Akkaraju reported an acquisition of 1,214,582 shares of common stock on May 21, 2025, as part of the merger with ACELYRIN, Inc., increasing his indirect beneficial ownership to 4,801,370 shares.

AyurMaya Capital Management Company, LP and David E. Goel have reported a significant increase in their beneficial ownership of Alumis Inc. common stock, acquiring over 4.4 million shares as part of a merger agreement.

ALUMIS INC. Director Patrick Machado has reported the acquisition of common stock and conversion of multiple stock options into ALUMIS shares following the completion of the merger with ACELYRIN, Inc.

James B. Tananbaum, a director and 10% owner of Alumis Inc., reported the acquisition of common stock through indirect holdings.

Foresite Labs, a significant shareholder in Alumis Inc. (ALMS), has increased its indirect holdings through recent common stock purchases.

Foresite Capital Management and affiliated funds report acquiring additional shares of Alumis Inc. common stock in early May 2025, increasing their indirect beneficial ownership.

Director Srinivas Akkaraju reports acquiring additional Alumis Inc. (ALMS) common stock through transactions by Samsara BioCapital, L.P., where he holds indirect beneficial ownership.